Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Paper by Andrea DeCensi indexed on Europe PMC as PubMed record 31479306, in Journal of Clinical Oncology (2019), one of the most cited records naming an author with this name at E.O. Ospedali Galliera.
Overview
Purpose: To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding to use endocrine therapy for breast cancer risk reduction.
Methods: An Expert Panel conducted targeted systematic literature reviews to identify new studies.
Results: A randomized clinical trial that evaluated the use of anastrozole for reduction of estrogen receptor-positive breast cancers in postmenopausal women at increased risk of developing breast cancer provided the predominant basis for the update.
Updated recommendations: In postmenopausal women at increased risk, the choice of endocrine therapy now includes anastrozole (1 mg/day) in addition to exemestane (25 mg/day), raloxifene (60 mg/day), or tamoxifen (20 mg/day). The decision regarding choice of endocrine therapy should take into consideration age, baseline comorbidities, and adverse effect profiles. Clinicians should not prescribe anastrozole, exemestane, or raloxifene for breast cancer risk reduction to premenopausal women. Tamoxifen 20 mg/day for 5 years is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. Data on low-dose tamoxifen as an alternative to the standard dose for both pre- and postmenopausal women with intraepithelial neoplasia are discussed in the Clinical Considerations section of this article. Additional information is available at www.asco.org/breast-cancer-guidelines.
Indexed on Europe PMC as PubMed record 31479306 (DOI 10.1200/jco.19.01472). Its author list gives "DeCensi A" with the affiliation "National Hospital E.O. Ospedali Galliera S.C. Oncologia Medica, Genoa, Italy; and Queen Mary University of London, United Kingdom", which names E.O. Ospedali Galliera; that is how the record was matched to Andrea DeCensi, and no figure has been checked by an editor.
One of the most cited papers Europe PMC returns for Andrea DeCensi at E.O. Ospedali Galliera, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
- Matched to the person by surname, initials and an affiliation string naming the institution on the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- Two authors sharing a surname, initials and institution cannot be told apart by this method; the person's profile links are the place to confirm authorship.